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Abstract
Background:  In endemic areas, falciparum malaria remains the leading cause of seizures in
children presenting to emergency departments. In addition, seizures in malaria have been shown to
increase morbidity and mortality in these patients. The management of seizures in malaria is
sometimes complicated by the refractory nature of these seizures to readily available anti-
convulsants. The objective of this study was to determine predictors of anti-convulsant treatment
failure and seizure recurrence after initial control among children with malaria.
Methods: In a previous study, the efficacy and safety of buccal midazolam was compared to that
of rectal diazepam in the treatment of prolonged seizures in children aged three months to 12 years
in Kampala, Uganda. For this study, predictive models were used to determine risk factors for anti-
convulsant treatment failure and seizure recurrence among the 221 of these children with malaria.
Results: Using predictive models, focal seizures (OR 3.21; 95% CI 1.42–7.25, p = 0.005), cerebral
malaria (OR 2.43; 95% CI 1.20–4.91, p = 0.01) and a blood sugar ≥200 mg/dl at presentation (OR
2.84; 95% CI 1.11–7.20, p = 0.02) were independent predictors of treatment failure (seizure
persistence beyond 10 minutes or recurrence within one hour of treatment). Predictors of seizure
recurrence included: 1) cerebral malaria (HR 3.32; 95% CI 1.94–5.66, p < 0.001), 2) presenting with
multiple seizures (HR 2.45; 95% CI 1.42–4.23, p = 0.001), 3) focal seizures (HR 2.86; 95% CI 1.49–
5.49, p = 0.002), 4) recent use of diazepam (HR 2.43; 95% CI 1.19–4.95, p = 0.01) and 5) initial
control of the seizure with diazepam (HR 1.96; 95% CI 1.16–3.33, p = 0.01).
Conclusion: Specific predictors, including cerebral malaria, can identify patients with malaria at
risk of anti-convulsant treatment failure and seizure recurrence.
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Background
In endemic areas, falciparum malaria remains the leading
cause of seizures in children presenting to emergency
departments [1-4]. In addition, seizures are the most com-
mon neurological complication of severe malaria, often
resulting in hospital admission, and seizures have been
shown to increase morbidity and mortality in these
patients [1,4,5]. The management of seizures in malaria is
complicated, as they may be refractory to readily available
anti-convulsants and there is concern for drug induced
respiratory depression [6].
Uncontrolled seizures in malaria can damage the brain by
aggravating hypoxia, hypoglycaemia and intracranial
hypertension, and in children with cerebral malaria they
have been shown to increase the risks of neurological
complications, cognitive impairment and death [5,7-10].
In addition, children with malaria and complicated sei-
zures are at a significantly higher risk of developing epi-
lepsy as compared to children without this complication
[11].
Diazepam administered intravenously or rectally is the
recommended first-line treatment for seizures in children
with malaria [6,12]. However, use of diazepam is charac-
terized by high failure rates, particularly with the rectal
route of administration [13]. Even when seizures are con-
trolled, relapse rates are high, probably due to the short
duration of action of diazepam in the brain [6,13]. This
limitation leads to repeated administration of diazepam,
largely in settings where alternative safe and effective anti-
convulsants are not available [14]. The key danger with
repeated dosing of diazepam is respiratory depression
[13,15], an uncommon occurrence with appropriate dos-
ing of the drug [16]. Furthermore, the use of phenobarbi-
tal, a readily available second-line agent, in addition to
diazepam may increase the risk of respiratory depression
[17]. A good therapeutic alternative to diazepam is mida-
zolam, which unlike diazepam is water-soluble and can
be administered through the buccal and nasal routes
[6,18,19]. Midazolam has been shown to be at least as
effective and safe as diazepam in the management of sei-
zures in children in Europe and in Africa [4,20-23].
Identification of patients at risk of failing anti-convulsant
treatment or experiencing recurrences of seizures after ini-
tial control is a practical step toward improving the care of
children with malaria complicated by seizures. If identi-
fied early these children could be provided with optimal
anti-convulsants to control seizures and minimize the risk
of respiratory depression. In this study, risk factors for
anti-convulsant treatment failure and seizure recurrence
among Ugandan children with malaria and prolonged sei-
zures were identified.
Methods
Study design
Results of a randomized trial to compare the efficacy and
safety of buccal midazolam versus rectal diazepam in chil-
dren with persistent seizures were reported previously [4].
The study was conducted between November 2005 and
June 2006 in the Acute Care Unit (ACU), the paediatric
emergency unit of Mulago Hospital, the national referral
hospital in Kampala, Uganda. Patients were enrolled if
they fulfilled the following criteria: (1) three months to 12
years of age, (2) no documented evidence of having
received IV diazepam or IV phenobarbital within 24 hours
prior to presentation, (3) documented seizure persisting
for more than five minutes at the time of administration
of study drug, and (4) provision of informed consent to
continue participation in the study. In view of practical
limitations, informed consent was waived upon emer-
gency presentation. Written consent to continue participa-
tion in the study was subsequently sought from parents or
legal guardians as soon as was practically possible after
initial evaluation and treatment.
Patients were randomly assigned to one of two treatment
arms: rectal diazepam and buccal placebo or rectal pla-
cebo and buccal midazolam. Parenteral preparations of
both diazepam (Roche, France) and midazolam (Roche,
France) were prepackaged by a pharmacist in two boxes
that corresponded to the two treatment arms. Boxes were
stored at 5–10°C and emptied and refilled on a weekly
basis. Diazepam and placebo were packaged in 2 ml glass
syringes and buccal midazolam and placebo were pack-
aged in 2 ml plastic syringes. Both re-packaged mida-
zolam and diazepam are stable under these conditions for
up to one month [24-26]. Both drugs were administered
at approximately 0.5 mg/kg (2.5 mg for age 3 to11
months; 5 mg for age 1 to 4 years; 7.5 mg for age 5 to 9
years; 10 mg for age10 to12 years). The primary study out-
come was cessation of visible seizure activity within 10
minutes of receiving study medications without recur-
rence in the subsequent one hour. If the seizure persisted
beyond 10 minutes or recurred within one hour after ini-
tial control, the child was categorized as a treatment fail-
ure. Secondary outcome measures included: 1)
proportion with cessation of convulsions within ten min-
utes, 2) proportion with seizure recurrence in subsequent
hour and within 24 hours after initial control and 3) time
to seizure recurrence. Any child presenting with fever,
with asexual forms of Plasmodium falciparum detected in
the blood, and without another illness explaining the
clinical state was considered to have malaria. Cerebral
malaria was defined as a child unable to localize painful
stimuli with persistence of coma (Blantyre coma score ≤
2) for more than an hour after control of the seizure, with
peripheral parasitaemia and after the exclusion of other
causes of encephalopathy, in particular central nervousMalaria Journal 2009, 8:145 http://www.malariajournal.com/content/8/1/145
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system infections and hypoglycaemia [27]. Seizures were
classified as focal, general, or focal with secondary gener-
alization [28].
The Uganda National Council for Science and Technology
and the institutional review boards of Makerere Univer-
sity, Kampala and the University of California, San Fran-
cisco approved the study.
Data analysis
Statistical analysis was done using Stata 10.0 (Stata Corp,
College Station, TX, USA). Multivariate analysis using
logistic regression was used to identify predictors of treat-
ment failure. Associations between potential predictors
for treatment failure were assessed using cross-tabulations
with chi-squared tests. The final model was selected using
the Stata 10.0 backward selection procedure set at p < 0.20
and it included: 1) duration of seizures prior to receiving
treatment, 2) form of disease (cerebral malaria vs. other
forms of severe malaria), 3) seizure type, 4) age and 5)
blood sugar level. For survival analysis, differences in sur-
vival functions between potential explanatory predictors
of seizure recurrence were initially compared using Kap-
lan Meier curves and the log rank test. The Cox propor-
tional hazard model was applied to assess the
independent roles of potential predictors of seizure recur-
rence. Covariates with a significant log rank test (p ≤
0.004) were included in the final model. Anti-convulsant
treatment received to terminate the seizure was included
in both the logistic regression model and Cox model to
determine any associations between treatment received
and treatment failure or seizure recurrence, respectively.
In the Cox model, time analysis was restricted to the first
12 hours after initial control, a period when most (92%)
of the seizures had recurred, and the proportional hazard
assumption was not violated.
Results
Patient recruitment and baseline characteristics
Of the 330 patients enrolled in the clinical trial, 221
(67%) had malaria and were analysed for outcomes of
interest (Figure 1). Of the 221 patients with malaria, 165
(75%) had their seizure controlled within 10 minutes of
receiving study medications. Of these, six (3%) patients
who received phenorbarbital were excluded from the final
analysis. Of the 159 evaluable study patients whose sei-
zures were controlled in the initial 10 minutes, 65 (41%)
experienced a seizure recurrence in the subsequent 24
hours. Of the 221 seizures occurring in malaria patients,
142 (64%) were associated with a fever, and 48 (22%)
were observed in children diagnosed with cerebral
malaria. Characteristics of seizure types in patients who
had cerebral malaria and those with other forms of
malaria were similar (Table 1). However, patients with
cerebral malaria had greater age (p < 0.001) and were
more likely to have experienced multiple seizures (p =
0.03) compared to those who had other types of malaria.
Predictors of treatment failure
In univariate analysis, the following factors were associ-
ated with an increased risk of anti-convulsant treatment
failure: focal seizures, cerebral malaria, and blood glucose
at presentation ≥ 200 mg/dl (11 mmol/l) (Table 2). In
multivariate analysis, focal seizures, cerebral malaria, and
hyperglycaemia remained as significant predictors of anti-
convulsant treatment failure (Table 2). In addition, com-
pared to midazolam, diazepam was not associated with a
significant risk of treatment failure (OR for failure with
diazepam 1.40; 95% CI 0.77–2.56, p = 0.26). This was in
contrast to the situation in patients who did not have
malaria, where diazepam was associated with a significant
risk of treatment failure (56% vs. 26.5%; RR 2.11, 95% CI
1.26–3.54, p = 0.002) as we reported previously [4].
Predictors of seizure recurrence were also assessed using
survival analysis (Figure 2). In addition to focal seizures
and cerebral malaria, history of multiple seizures or prior
Table 1: Baseline characteristic of patients enrolled in the study
Type of malaria
Characteristic Cerebral malaria Non-cerebral malaria
Number 48 173
Gender (% female) 19 (40%) 90 (52%)
Number of seizures 3 (2–5.5) a 2 (1–4) a
Focal seizures (%) 7 (15%) 25 (14%)
Age (months) 28 (17–42)b 17 (12–30)b
Age range(months) 4–117 3–99
Blood glucose level at presentation 113 (75–172) 116 (88–155)
NOTE. All results are medians (IQR) unless otherwise specified. Within 24 hours before enrollment
a p = 0.02
b p < 0.001Malaria Journal 2009, 8:145 http://www.malariajournal.com/content/8/1/145
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use of diazepam was associated with a significant risk of
seizure recurrence (p ≤ 0.004 for all comparisons).
In the final Cox proportional hazard model (Table 3), the
following factors remained significant predictors of sei-
zure recurrence in the subsequent 12 hours: 1) focal sei-
zures (HR 2.86; 95%CI 1.49–5.49, p = 0.002), 2) multiple
seizures (HR 2.45; 95%CI 1.42–4.23, p = 0.001, 3) cere-
bral malaria (HR 3.32; 95%CI 1.94–5.66, p < 0.001), 4)
use of diazepam within 24 hours prior to enrollment in
the study (HR 2.43 95%CI 1.19–4.95, p = 0.01), and 5)
treatment with diazepam to control a seizure (HR 1.96;
95%CI 1.16–3.33, p = 0.011).
Discussion
Predictors of anti-convulsant treatment failure and seizure
recurrence were evaluated in Ugandan children presenting
to an emergency unit with malaria complicated by pro-
longed seizures. Presenting with cerebral malaria, focal
seizures, or hyperglycaemia were found to be independ-
ent predictors of anti-convulsant treatment failure. Predic-
tors of seizure recurrence after initial control with an anti-
convulsant included presenting with cerebral malaria,
focal seizures, or multiple seizures. In addition, compared
to midazolam, prior use of diazepam or initial control of
a seizure with diazepam were associated with an increased
hazard of experiencing a recurrence. Of note, in children
with malaria, focal seizures and cerebral malaria were
found to be important markers of refractory seizures, con-
sidering that they were associated with both anti-convul-
sant treatment failure and seizure recurrence.
In this study, children with malaria who presented with
focal seizures were more likely to fail treatment than those
with other seizure types. This finding is consistent with
prior reports that focal seizures are a risk factor for refrac-
tory status epilepticus in adults [29]. One possible expla-
nation for this finding is that, in contrast to generalized
seizures, focal seizures may be associated with a localized
structural injury representative of serious underlying brain
pathology. Children presenting with cerebral malaria
were also more likely to fail treatment, which is not sur-
prising considering the severe nature of this syndrome
[30]. Baseline hyperglycaemia (glucose value ≥ 200 mg/
dl) (11 mmol/l) was found to be a risk factor for treatment
failure. Stress hyperglycaemia, a known complication in
critically ill children, has been associated with increased
mortality [31-33]. It is possible that, in children with
severe malaria, hyperglycaemia is a surrogate marker of
ongoing serious brain disease [33]. As previously
Study profile Figure 1
Study profile.
Enrolled 330 patients randomized to treatment  
221 (67%) patients with malaria  
109 (33%) patients without malaria   
165 (75%) seizures controlled in the 
first 10 minutes    
Excluded 6 (3%) patients 
who received 
phenobarbital 
65 (41%) patients experience a seizure 
recurrence after initial control 
75 (34%) fail treatment 
 Malaria Journal 2009, 8:145 http://www.malariajournal.com/content/8/1/145
Page 5 of 8
(page number not for citation purposes)
reported, considering all children with prolonged sei-
zures, diazepam was associated with a significant risk of
treatment failure compared to midazolam [4]. Consider-
ing the impact of malaria, children with prolonged sei-
zures and malaria who received diazepam, but not those
who received midazolam, were less likely to fail treatment
compared to those without malaria [4]. This finding of
decreased failures of diazepam in children with malaria
contrasts with findings of another recent trial [34], per-
haps due to differences in study design.
Risk factors for seizure recurrence in children with malaria
have not been well characterized. Predictors of seizure
recurrence in patients without malaria include presenta-
tion with multiple or focal seizures [35]. In this study of
children with malaria, focal seizures, cerebral malaria,
and presenting with multiple seizures were all independ-
ent risk factors for seizure recurrence. In addition, seizures
that were controlled with diazepam were significantly
more likely to recur in the subsequent 12 hours as com-
pared to those controlled by midazolam. This finding sug-
gests that, in the absence of alternative anti-convulsants,
diazepam is likely to be administered repeatedly, expos-
ing patients to the risk of drug induced respiratory depres-
sion [15,27], a complication that may commonly be fatal
in rural sub-Saharan Africa, where assisted ventilation is
generally unavailable [6,16]. In addition, diazepam
induced respiratory depression may increase mortality in
children with severe malaria by suppressing control of
metabolic acidosis and/or increased intracranial pressure
[16,13,14,17].
These predictors can be used to identify children with
malaria who may benefit from alternative therapy, in the
particular the use of longer-acting and safer acting anti-
convulsants, such as midazolam or lorazepam. More stud-
ies are urgently needed to evaluate the effectiveness and
prophylactic benefit of longer acting agents in the treat-
ment of seizures in children with malaria.
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Table 2: Univariate and multivariate analysis for factors predicting treatment failure
Univariate Multivariate
Variable Number of treatment failures Odds ratio 95% CI p-value Odds ratio 95%CI p-value
Type of seizure
Generalized seizure 56 - - 1 - -
Focal seizure 19 3.47 1.57–7.67 <0.001 3.21 1.42–7.25 0.005
Form of disease
Non-cerebral malaria 52 - - 1 - -
Cerebral malaria 23 2.14 1.10–4.15 0.02 2.43 1.20–4.91 0.01
Recent use of diazepam
No 65 - - a
Yes 10 1.88 0.75–4.70 0.16 a
Pre-treatment blood glucose 
level
< 200 mg/dl 62 1 - 1
≥ 200 mg/dl 13 2.85 1.16–6.95 0.01 2.84 1.11–7.20 0.02
Age
> 11 months 54 1 - 1
< 12 months 21 1.88 0.96–3.67 0.06 1.99 0.96–4.13 0.06
Number of seizures
< 3 38 1 - a
≥ 3 37 1.18 0.80–2.56 0.21 a
Treatment received
Midazolam 37 1 - 1
Diazepam 38 1.21 0.69–2.11 0.50 1.40 0.77–2.56 0.26
Unconscious prior to onset of 
seizure
No 35 1 - a
Yes 37 1.60 0.90–2.85 0.11 a
a Not included in the final model.Malaria Journal 2009, 8:145 http://www.malariajournal.com/content/8/1/145
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Kaplan-Meier plots of time to first seizure recurrence within 24 hours after initial control for the subgroups indicated Figure 2
Kaplan-Meier plots of time to first seizure recurrence within 24 hours after initial control for the subgroups 
indicated. Figure 2 shows Kaplan Meier survival plots showing time to seizure recurrence within 24 hours after initial control 
of the seizure in the following subgroups of patients: A. Malaria type: Cerebral malaria vs. non-cerebral malaria. B. Seizure type: 
Focal seizures vs. generalized seizures. C. Seizure frequency *: > 2 vs. < 3. D. Prior treatment with diazepam*: Received 
diazepam vs. did not receive diazepam. * 24 hours prior to presentation to the acute care unit.
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  D  Time to seizure recurrence in hours 
Number at risk  
Non cerebral malaria              126               98             94                86              84                0     Gen      141            107              100              90               88                 0 
 Cerebral malaria                      33               17              12                10              10                0     Focal    18                8                  6                 6                 6                  0 
Number of seizures > 2             78               49             42                37              33                0   No use     16               7                 7                5                 5                0  
Number of seizures <3              81               66             64                59              57                0   Used       143            108              99              91               89               0 
Number at risk       Number at risk  
Number at risk  
p= 0.004 
p= 0.002 
p= 0.002 
p < 0.001  
No use of diazepam 24 hours prior to enrollment  
Table 3: Cox model for predictors of seizure recurrence within 12 hours after initial control
Characteristic Hazard ratio 95% CI p-value
Focal seizure 2.86 1.49–5.49 0.002
Number of seizures prior to treatment: ≥ 3 2.45 1.42–4.23 0.001
Cerebral malaria 3.32 1.94–5.66 < 0.001
Recent use of diazepam 2.43 1.19–4.95 0.01
Treatment with diazepam vs. midazolam 1.96 1.16–3.33 0.01Malaria Journal 2009, 8:145 http://www.malariajournal.com/content/8/1/145
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